Given that both diabetes and obesity confer high psychiatric disorder risks, an increasing number of researchers have begun investigating a potential relationship between the use of GLP-1 RAs and the occurrence of psychiatric AEs (23–25). Here, GLP1R is linked to psychiatric disorder.